Changes in Hong Kong stocks | Diakang Shiyun-B (02592) is now up more than 4%. The subsidiary will discuss CBT-004 research and development matters with the US FDA

The Zhitong Finance App learned that Diakangshiyun-B (02592) is now up more than 4%. As of press release, it has risen 4.13% to HK$8.58, with a turnover of HK$11.824,300.

According to the news, Baokangshiyun previously announced that Cloudbreak USA, a wholly-owned subsidiary of the company registered in California, USA, is scheduled to officially hold a Phase 2 post-clinical trial meeting with the US Food and Drug Administration on December 10, 2025. The meeting involves the Group's clinical-stage drug candidate CBT-004. This Phase 2 post-clinical trial conference is an important milestone in the CBT-004 development process. It is used to discuss requirements related to potential phase 3 clinical trial development and new drug applications in the CBT-004 development process.